April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Expert Considers First- and Second-Line Liver Cancer Treatment Options in 2 HCC Case Studies
July 5th 2019Aiwu Ruth He, MD, PhD, discusses treatment options in a <em>Targeted Oncology </em>live case-based peer perspectives discussion based on 2 case studies of patients with hepatocellular carcinoma.
Read More
High Response Rate Seen With Concurrent Ibrutinib Plus CAR T-Cell Therapy in High-Risk CLL
June 26th 2019Significant activity was observed when ibrutinib was administered concurrently with CD19-directed CAR T-cell therapy compared with separately in patients with high-risk relapsed/refractory chronic lymphocytic leukemia who had progressed on or were intolerant of ibrutinib. Data presented at the 15th International Conference on Malignant Lymphoma show a high response rate with this concurrent treatment.
Read More
Phase III CheckMate 459 Trial in Unresectable HCC Misses Primary Endpoint
June 24th 2019Topline results from the phase III CheckMate 459 trial revealed that the trial did not meet its primary endpoint of improved overall survival with nivolumab as compared with sorafenib for the treatment of patients with newly diagnosed, unresectable hepatocellular carcinoma.
Read More
Treatment Patterns at End of Life Explored in Large, National Database
June 20th 2019The American Cancer Society, Dana-Farber Cancer Institute, Baptist Cancer Center, and the Mayo Clinic report that treatment patterns varied markedly by cancer type and care facility setting for patients with de novo metastatic disease who died within 1 month after diagnosis, based on an analysis of data from 100,848 patients collected from the National Cancer Database, a hospital-based cancer registry that captures 70% of patients in the United States with a new diagnosis.
Read More
FDA Issues Draft Guidance to Broaden Clinical Trial Inclusion
June 19th 2019The FDA recently released 5 new draft guidance documents that promote broader patient eligibility for cancer clinical trials. The policies encourage inclusion of certain individuals who were previously disqualified due to medical conditions or biological factors, including brain metastases, organ dysfunction, prior or concurrent malignancies, chronic infections, and age.
Read More
Strategies to Engage Underrepresented Populations Improves Inclusivity in Clinical Trials
June 17th 2019A cohort of cancer centers was selected to serve as models for identifying key strategies for racial and ethnic minority group engagement in clinical trials. On the basis of several qualifying criteria, such as sustained accrual of minorities into clinical cancer research, an established minority population ≥10% in the overall catchment, an established clinical trial infrastructure, and a formal community outreach program, the investigators identified 8 cancer centers for participation.
Read More
Novel Combinations Explored in CRC With Rare Gene Mutations
June 15th 2019In a case-based-style discussion, Tanios S. Bekaii-Saab, MD, and Wells Messersmith, MD, reviewed the treatment of patients with colorectal cancer whose tumors express rare gene mutations or molecular signatures, such as <em>NTRK</em> fusions.
Read More
Zhu Reviews the Approval of Second-Line Ramucirumab for AFP-Elevated HCC
June 14th 2019In an interview with <em>Targeted Oncology, </em>Andrew X. Zhu, MD, PhD, FACP, discussed the results from the REACH-2 trial and the significance of the approval of ramucirumab monotherapy in patients with advanced HCC and high AFP levels who have previously failed sorafenib.
Read More
Sorafenib Plus HAIC Demonstrates Benefit for Patients With HCC and Portal Vein Invasion
June 14th 2019Sorafenib in combination with hepatic arterial infusion chemotherapy demonstrated an improvement in overall survival compared with sorafenib alone for patients with hepatocellular carcinoma and portal vein invasion, according to the results of a randomized phase III trial.
Read More
Bekaii-Saab Considers TKI Therapy to Treat Patients With Advanced GI Cancers
June 13th 2019During a recent <em>Targeted Oncology </em>live case-based peer perspectives presentation, Tanios Bekaii-Saab, MD, discussed with a group of physicians the treatment options for patients with gastrointestinal cancers and the characteristics that influence his decision making. Bekaii-Saab explained his clinical decisions based on the case scenario of one patient with colorectal cancer and one with hepatocellular carcinoma.
Read More
Tumor Characteristics May Help Guide Therapy Choice in HCC
June 13th 2019Determining the optimal therapy strategy for hepatocellular carcinoma when patients are eligible for multiple different agents in clinical practice requires detailed analysis of patient- and tumor-specific characteristics.
Read More
Sorafenib Plus Chemo Combo Shows Benefit in Advanced HCC, But Phase III Trial Not Warranted
May 24th 2019The combination of sorafenib plus gemcitabine and oxaliplatin demonstrated “moderate” benefits compared with sorafenib monotherapy in patients with advanced hepatocellular carcinoma, according to findings from an open-label phase II trial recently published in the <em>British Journal of Cancer.</em>
Read More
Ramucirumab Approved by FDA for Second-Line Treatment of AFP-Elevated HCC
May 11th 2019Ramucirumab monotherapy has received an approval from the FDA for the treatment of patients with hepatocellular carcinoma who have an alpha fetoprotein of ≥400 ng/mL and have been previously treated with sorafenib.
Read More
Exploring Challenges in the Treatment of HCC
April 29th 2019Ahmed Omar Kaseb, MD, associate professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, says 2 major challenges in hepatocellular carcinoma are the lack of effective treatments and the co-existing underlying chronic liver disease.
Watch